Skip to main content
ASSURE TECH (HANGZHOU) CO., LTD. logo

ASSURE TECH (HANGZHOU) CO., LTD. — Investor Relations & Filings

Ticker · 688075 ISIN · CNE100004ZC0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 449 across all filing types
Latest filing 2026-05-21 Declaration of Voting R…
Country CN China
Listing Shanghai Stock Exchange 688075

About ASSURE TECH (HANGZHOU) CO., LTD.

https://www.diareagent.com/

Assure Tech (Hangzhou) Co., Ltd. is a biotechnology enterprise specializing in the research, development, and manufacturing of in vitro diagnostic (IVD) reagents and clinical testing instruments. The company focuses on rapid diagnostic tests and Point of Care Testing (POCT) solutions across various medical fields, including infectious diseases, drug of abuse screening, oncology, cardiac markers, and fertility. Utilizing advanced lateral flow immunoassay technology, Assure Tech provides diagnostic tools designed for accuracy and efficiency in clinical and laboratory settings. The company adheres to international quality standards, maintaining ISO 13485 certification and obtaining regulatory clearances such as FDA and CE marks for its product range. Through its integrated R&D and production infrastructure, Assure Tech supplies a diverse portfolio of diagnostic products to a global customer base.

Recent filings

Filing Released Lang Actions
安旭生物2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is the official公告 of the 2025 Annual General Meeting resolutions for 杭州安旭生物科技股份有限公司, detailing shareholder attendance and voting results on each proposal. This matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-05-21 Chinese
上海市锦天城律师事务所关于安旭生物2025年度股东会法律意见书
Regulatory Filings Classification · 73% confidence The document is a lawyer’s legal opinion letter regarding the 2025 annual shareholders’ meeting, detailing convening procedures, attendance, and voting results. It is not an AGM presentation (AGM-R), nor a full annual report or audit report, nor a proxy statement. It represents a compliance/legal disclosure rather than the meeting materials themselves. Therefore it falls under the fallback category for general regulatory/compliance filings: RNS.
2026-05-21 Chinese
上海锦天城（杭州）律师事务所关于安旭生物终止实施2024年限制性股票激励计划的法律意见书
Audit Report / Information Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the termination of a 2024 restricted stock incentive plan by a company. It references relevant laws and regulations, details the approval and authorization process, and confirms compliance with disclosure obligations. The document is a standalone legal opinion and does not contain financial statements, audit results, or management discussion of financial performance. It is not an annual report, interim report, earnings release, or any other financial report type. It is also not a regulatory announcement or a report publication announcement. The document fits the category of Audit Report / Information (AR) as it is a formal legal opinion related to a corporate action, providing legal assurance and compliance verification, which aligns with the scope of audit or legal reports related to corporate governance and regulatory compliance.
2026-04-29 Chinese
安旭生物关于召开2025年年度股东会的通知
AGM Information Classification · 95% confidence The document is a detailed notice about the convening of the 2025 Annual General Meeting (AGM) of Hangzhou Anxu Biotechnology Co., Ltd., including the date, location, voting methods, agenda items, and instructions for shareholders. It includes information about the meeting's agenda, such as the 2025 annual report, financial statements, profit distribution plan, auditor appointment, and other shareholder proposals. The document does not contain the actual annual report or financial statements but rather the notification and procedural details for the AGM. The document length is 3856 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting, including notices and agendas.
2026-04-29 Chinese
安旭生物2025年度独立董事述职报告（程乐）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Annual Report" for the year 2025 from a specific independent director of the company. It details the director's duties, attendance at meetings, communication with auditors, oversight of financial reports, and governance activities during the year. It is a detailed report on the director's work and governance oversight rather than a financial report or announcement. The document length is 4180 characters, which is relatively short but contains substantive content about board and management activities, not just an announcement or certification. This fits best under Board/Management Information (MANG), which covers announcements related to board or senior management activities and reports on their duties and changes. It is not an Annual Report (10-K) or Audit Report (AR) because it does not contain full financial statements or audit opinions. It is not a Regulatory Filing (RNS) because it is a formal report by a board member on their duties and activities. Therefore, the classification is MANG with high confidence.
2026-04-29 Chinese
安旭生物2025年度会计师事务所履职情况评估报告
Audit Report / Information Classification · 95% confidence The document is titled as an evaluation report on the performance of the accounting firm for the year 2025, specifically regarding their audit services for the company's annual report and internal control audit. It details the auditor's qualifications, audit scope, communication with management, and the conclusion that the audit report was unqualified. The document is not the annual report itself but an assessment of the auditor's performance in relation to the annual audit. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and evaluations of audit firms' performance. The document length is 1541 characters, which is short but contains substantive content about the audit process and results, not merely an announcement or certification. Therefore, it should be classified as AR.
2026-04-29 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.